These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 38558097)
21. Antazoline for pharmacologic cardioversion of atrial fibrillation: teaching an old drug new tricks. Lip GYH; Mills MT Pol Arch Intern Med; 2024 Apr; 134(4):. PubMed ID: 38666721 [No Abstract] [Full Text] [Related]
22. Giant P waves after pharmacological cardioversion of atrial fibrillation. Catapano-Minotti G; Corsonello A; Antonelli Incalzi R Intern Emerg Med; 2009 Apr; 4(2):169-70. PubMed ID: 19050836 [No Abstract] [Full Text] [Related]
23. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. Oral H; Souza JJ; Michaud GF; Knight BP; Goyal R; Strickberger SA; Morady F N Engl J Med; 1999 Jun; 340(24):1849-54. PubMed ID: 10369847 [TBL] [Abstract][Full Text] [Related]
27. Electrical and pharmacologic cardioversion for atrial fibrillation. Kim SS; Knight BP Cardiol Clin; 2009 Feb; 27(1):95-107, ix. PubMed ID: 19111767 [TBL] [Abstract][Full Text] [Related]
28. Rapid cardioversion of new onset atrial fibrillation with ibutilide in the emergency department. Ryan DT; Cummins FH; Fahy GJ Ir Med J; 2005 Sep; 98(8):241-2. PubMed ID: 16255117 [TBL] [Abstract][Full Text] [Related]
29. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Sedgwick ML; Lip G; Rae AP; Cobbe SM Int J Cardiol; 1995 Apr; 49(2):159-66. PubMed ID: 7628887 [TBL] [Abstract][Full Text] [Related]
31. Calcium-activated potassium current: a novel ion channel candidate in atrial fibrillation. Nattel S J Physiol; 2009 Apr; 587(Pt 7):1385-6. PubMed ID: 19336611 [No Abstract] [Full Text] [Related]
32. Novel molecular targets for atrial fibrillation therapy. Dobrev D; Carlsson L; Nattel S Nat Rev Drug Discov; 2012 Mar; 11(4):275-91. PubMed ID: 22460122 [TBL] [Abstract][Full Text] [Related]
33. The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation. McBride BF J Clin Pharmacol; 2009 Mar; 49(3):258-67. PubMed ID: 19246727 [TBL] [Abstract][Full Text] [Related]
34. Pharmacologic Cardioversion of Paroxysmal Atrial Fibrillation in the Emergency Department in the Novel Anticoagulants' Era. Tsiachris D; Doundoulakis I; Tsioufis K Cardiovasc Drugs Ther; 2022 Dec; 36(6):1253-1254. PubMed ID: 35218470 [No Abstract] [Full Text] [Related]
39. Pharmacologic relevance of K(+)Channel remodeling in atrial fibrillation. Van Wagoner DR J Mol Cell Cardiol; 2000 Oct; 32(10):1763-6. PubMed ID: 11013120 [No Abstract] [Full Text] [Related]
40. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Hohnloser SH; van de Loo A; Baedeker F J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]